Abstract

Introduction Current recommendations for hypertension management in patients with LVADs include the use of neurohormonal antagonists, such as RAAS inhibitors and beta-blockers (BB). HeartMate3 (HM3) LVAD device package insert recommends a goal MAP Methods A single-center, retrospective chart review was conducted for patients with HM3 implantation from 2015-2018. Demographic, medication, laboratory and clinical outcomes data were extracted from an internal database. Patients who died prior to discharge were excluded. Results Patients (n=87) were predominantly Caucasian (82.8%) men (71.3%) with a mean age of 58.1 ± 10.9 years. Co-morbidities included DM (41.4%), hypertension (52.9%), CKD (21.8%) and arrhythmias (62.1%). A MAP of 80-90 mm Hg was achieved in 32% of patients at discharge and in 51% at 6-months (Figure 1A). At discharge, 11.5% of patients were on a RAAS inhibitor, BB and mineralocorticoid receptor antagonists (MRA) compared to 28.7% at 6-months (Figure 1B). Creatinine and MAP did not differ by drug class. The secondary composite outcome at 6-months occurred in 35.8% of patients overall (3 events in patients treated with a combination of RAAS inhibitor with BB and MRA vs 13 in patients without any medical therapy). Conclusion There was an overall increase in systemic blood pressure following surgical recovery 6-months post-HM3 implant, with more than 90% of the cohort sustaining a MAP >80 mm Hg and 40% >90 mm Hg. GDMT with a RAAS inhibitor, BB and MRA was low at discharge (11.5%) with only marginal improvement at 6-months (28.7%), despite adequate MAPs. Factors limiting the titration of GDMT in this population, despite adequate MAP control, warrants further quality improvement investigation.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call